10-Q: Recursion Pharma Reports Q2 2026 Results, Revenue Down 60%

Recursion Pharmaceuticals, Inc. reported a significant decrease in total revenue for the second quarter of 2026, alongside continued substantial operating losses, while highlighting progress in key collaborations and internal pipeline development.

Summary

• Recursion Pharmaceuticals reported total revenue of $7.7 million for the three months ended June 30, 2026, a 60% decrease from $19.2 million in the same period last year.
• For the six months ended June 30, 2026, total revenue was $14.1 million, down 58% from $34.0 million in the prior year.
• The company incurred a net loss of $131.0 million for the three months ended June 30, 2026, compared to a net loss of $171.9 million in the same period last year.
• For the six months ended June 30, 2026, the net loss was $248.5 million, an improvement from $374.4 million in the prior year.
• As of June 30, 2026, the company had $556.8 million in cash, cash equivalents, and restricted cash, which is expected to fund operations for at least the next twelve months.
• The company advanced a neuroscience target with Genentech into early discovery and reported progress with Sanofi, with potential upcoming milestones in the next 6-12 months.
• Internal pipeline updates include expected FDA discussions for REC-4881 in the second half of 2026 and initiation of Phase 1/2 trial for REC-7735 in the second half of 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant revenue decline and continued substantial operating losses, despite progress in collaborations and pipeline development.

Positives

• Advancement of a neuroscience target with Genentech into an early discovery program, demonstrating the platform's ability to validate novel therapeutic targets.
• Progress in the joint portfolio with Sanofi, with potential for differentiated AI-enabled oral molecules to reach development candidate and late-stage discovery milestones within 6-12 months.
• The company expects its current cash and cash equivalents to be sufficient to fund operations for at least the next twelve months.
• REC-4881 has received Orphan Drug Designation and Fast Track Designation from the FDA.
• REC-7735, an AI-designed PI3K H1047R inhibitor, has an IND cleared and its Phase 1/2 clinical study is expected to initiate in the second half of 2026.
• The company has appointed Hoifung Poon, Ph.D., as Chief AI Officer and Donovan Chin, Ph.D., as Senior Vice President, Drug Design, strengthening its leadership team.
• Total revenue from the Roche and Genentech collaboration has reached $216 million in upfront and milestone payments.
• Total upfront and milestone payments from the Sanofi collaboration have reached $134 million.

Negatives

• Total revenue for the three months ended June 30, 2026, was $7.7 million, a 60% decrease from $19.2 million in the prior year.
• Total revenue for the six months ended June 30, 2026, was $14.1 million, a 58% decrease from $34.0 million in the prior year.
• The company incurred a net loss of $131.0 million for the three months ended June 30, 2026, and $248.5 million for the six months ended June 30, 2026.
• The accumulated deficit reached $2.3 billion as of June 30, 2026.
• Cost of revenue exceeded operating revenue for the three and six months ended June 30, 2026.
• Research and development expenses, while decreased, still represent a significant portion of operating expenses.
• The company's disclosure controls and procedures were found to be ineffective due to material weaknesses in internal control over financial reporting.
• The company anticipates needing to raise additional financing in the future to fund operations.

Risks

• The company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates.
• If the company is unable to access additional funds when needed, it may not be able to continue the development of its products or may be required to delay, scale back, or abandon development programs.
• The company's ability to access capital when needed is not assured and could materially harm its business, financial condition, and results of operations.
• The company is subject to risks and uncertainties similar to other biotechnology companies, including the uncertainty of clinical trial outcomes and the need for additional funding.
• The company has a history of operating losses.
• The company's U.S. net operating loss (NOL) and tax credit carryforwards may be subject to annual limitations under Section 382 of the Internal Revenue Code.
• The company may be involved in various legal proceedings arising in the normal course of business, and an unfavorable resolution could materially affect its financial position.
• The company's disclosure controls and procedures were ineffective due to material weaknesses in internal control over financial reporting.

Future Outlook

Recursion expects to continue incurring substantial operating losses and requires additional capital. The company believes its current cash and cash equivalents will fund operations for at least the next twelve months. Future financing will likely be necessary for operations and potential commercialization. The company anticipates needing to raise additional financing in the future.

Management Comments

• "The Genentech has exercised the first Validated Target Option under the companies' neuroscience collaboration, advancing a previously unexplored neuroscience target into a small molecule early discovery program."
• "The milestone provides additional early evidence that Recursion's AI-native platform can both discover and play a key role experimentally validating novel therapeutic targets in neuroscience."
• "Potential for differentiated AI-enabled oral molecules to reach development candidate and late-stage discovery milestones with Sanofi over the next 6-12 months."
• "Using Recursions Chemistry Platform to design a potential first-in-class molecule for the collaboration's neuroscience target announced today with Genentech."
• "Agentic AI is compounding Recursion's advantage across Biology, Design, and ClinTech."
• "We believe that our cash and cash equivalents will be sufficient to fund our operations for at least the next twelve months."

Industry Context

StockSavvy.ai notes that Recursion's results reflect the high-risk, high-reward nature of the biotechnology sector, particularly for clinical-stage companies relying on AI and platform technologies. The significant revenue decline, common in this industry before product commercialization, is offset by strategic partnerships and pipeline progress, which are key value drivers.

Comparison to Industry Standards

• The revenue decline of 60% for the quarter is substantial but not uncommon for clinical-stage biotechs in periods between major partnership milestones or before product approval.
• The continued net loss is typical for companies investing heavily in R&D, with companies like Moderna and BioNTech also experiencing significant losses during their development phases before COVID-19 vaccine commercialization.
• The company's cash runway of at least 12 months is a standard benchmark for operational stability, though many companies in this space seek to extend this through further funding rounds.
• The focus on AI-native platforms and partnerships with large pharmaceutical companies (Sanofi, Roche, Genentech, Merck) aligns with industry trends where AI is increasingly integrated into drug discovery to accelerate timelines and reduce costs.

Legal Proceedings

• Industry Office SLC, LLC v. Recursion Pharmaceuticals, Inc.: Landlord filed a lawsuit alleging anticipatory repudiation, breach of contract, and breach of the implied covenant of good faith and fair dealing, seeking monetary damages and attorneys fees. Recursion has filed counterclaims alleging breach of contract and fraudulent misrepresentation. Discovery is ongoing.

Stakeholder Impact

• Shareholders: Continued operating losses and the need for future capital raises may impact share price and dilution.
• Employees: Headcount reductions mentioned in G&A expenses could impact morale and workforce stability.
• Collaborators (Sanofi, Roche, Genentech, Merck): Progress in collaborations is positive, but the overall financial health of Recursion could impact the long-term viability of these partnerships.
• Creditors: The company's substantial accumulated deficit and reliance on equity financing suggest a higher risk profile for creditors.

Next Steps

• Discussions with FDA regarding the registrational path for REC-4881 are expected in 2H26.
• Phase 1/2 ZINNIA clinical study for REC-7735 is expected to be initiated in the second half of 2026.
• Additional Phase 1 dose escalation data for REC-1245 (RBM39) is expected in 2H26.
• Early Phase 1 safety and PK combination data for REC-617 (CDK7) is expected in 1H27.
• Early Phase 1 safety and PK monotherapy data for REC-3565 (MALT1) is expected in 1H27.
• Early Phase 1 safety and PK monotherapy data for REC-4539 (LSD1) is expected in 2H27.
• Continue to integrate Exscientia's operations into the company's system of internal control over financial reporting.

Key Dates

Recommendation

While Recursion Pharmaceuticals shows promising technological advancements and strategic partnerships, the significant revenue decline, persistent operating losses, and the need for future capital raises present considerable risks. The company's ability to execute on its pipeline and secure necessary funding will be critical. A 'hold' recommendation reflects a balance between the potential upside from its AI platform and the substantial financial and execution risks.

Keywords

drug discovery, AI, biotechnology, clinical stage, platform, collaboration, oncology, neuroscience